The estimated Net Worth of Michael Berman is at least 328 千$ dollars as of 12 May 2023. Mr. Berman owns over 122,497 units of InspireMD Inc stock worth over 328,292$ and over the last 12 years he sold NSPR stock worth over 0$. In addition, he makes 0$ as Independent Director at InspireMD Inc.
Michael has made over 3 trades of the InspireMD Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 122,497 units of NSPR stock worth 199,670$ on 12 May 2023.
The largest trade he's ever made was buying 122,497 units of InspireMD Inc stock on 12 May 2023 worth over 199,670$. On average, Michael trades about 10,136 units every 160 days since 2013. As of 12 May 2023 he still owns at least 122,497 units of InspireMD Inc stock.
You can see the complete history of Mr. Berman stock trades at the bottom of the page.
Michael Berman is Independent Director of the Company. He is a medical device entrepreneur who works with high-potential development and early-stage commercial companies. From 2005 to 2012, when the company was sold to Boston Scientific, Mr. Berman was a co-founder and the chairman of BridgePoint Medical, Inc., which developed technology to treat coronary and peripheral vascular chronic total occlusions. Mr. Berman was also a member of the board of Lutonix, Inc. from 2007 until 2011, when the company was sold to C.R. Bard, Inc. Mr. Berman has served (i) since 2003 as co-founder and a director of Aetherworks II, a medical device incubator, (ii) since 2004 as a co-founder and director of Benechill, Inc., a company developing a therapeutic hypothermia system for the treatment of cardiac arrest, (iii) since 2011 as an advisor to, and since 2012 as a director of, Cardiosonic, Inc., a company developing a system for hypertension reduction via renal denervation, (iv) since 2005 as a director of PharmaCentra, LLC, which creates customizable marketing programs that help pharmaceutical companies communicate with physicians and patients, (v) since 2011 as a co-founder and director of Rebiotix Inc., a company developing an innovative treatment for C Diff colitis, (vi) since 2011 as a director of AngioSlide Ltd., a medical device company that has developed an embolic capture angioplasty device, (vii) since 2011 as a director of InterValve, Inc., a medical device company developing an aortic valvuloplasty balloon for treatment of calcific aortic stenosis, (viii) since 2013 as a Director of ClearCut Inc., a medical device company that has developed an MRI system for tumor margin assessment, (ix) since 2013 as a director of PulmOne Ltd., a medical device company developing an innovative Pulmonary Function Testing system.
Michael Berman is 58, he's been the Independent Director of InspireMD Inc since 2013. There are 5 older and 5 younger executives at InspireMD Inc. The oldest executive at InspireMD Inc is Dr. Sol J. Barer Ph.D., 74, who is the Special Advisor to the Board.
Michael's mailing address filed with the SEC is C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV, L3, 6744832.
Over the last 13 years, insiders at InspireMD Inc have traded over 1,684,082$ worth of InspireMD Inc stock and bought 3,887,125 units worth 5,293,286$ . The most active insiders traders include Sol J Barer、Eli Bar、Gary S Roubin. On average, InspireMD Inc executives and independent directors trade stock every 97 days with the average trade being worth of 319,459$. The most recent stock trade was executed by Gary S Roubin on 30 November 2023, trading 50,000 units of NSPR stock currently worth 126,500$.
inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.
InspireMD Inc executives and other stock owners filed with the SEC include: